Efficacy Emollient on Xerosis in Children With Atopic Dermatitis
Information source: Pierre Fabre Medicament
Information obtained from ClinicalTrials.gov on December 08, 2011 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atopic Dermatitis
Intervention: V0034CR01B (Drug); Vehicle cream (Drug); desonide 0.1% cream (Drug); Foaming gel (Other)
Phase: Phase 3
Status: Recruiting
Sponsored by: Pierre Fabre Medicament Official(s) and/or principal investigator(s): Franck BORALEVI, Pr, Principal Investigator, Affiliation: Health centre
Overall contact: Pierre Fabre Medicament, Email: contact_essais_cliniques@pierre-fabre.com
Summary
Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local,
immunological, genetic and environmental factors. Important symptoms of atopic dermatitis
are dry skin, intense pruritus and impaired epidermal barrier function. Atopic dermatitis is
associated with skin barrier dysfunction that facilitates an easier allergen penetration
into the skin with an increased irritation and subsequent cutaneous inflammation. A lack of
important stratum corneum intercellular lipids and an inadequate ratio between compounds
enhance trans-epidermal water loss leading to xerosis. Skin hydration by emollient therapy
usually twice daily improves dryness and subsequently pruritus during the treatment of
atopic dermatitis and especially improves the barrier function. Emollients make part of
basic therapy (grade 1) for treatment of atopic dermatitis (European Academy of Dermatology
and Venereology Task Force 2009 Position Paper). Improvement of cutaneous barrier
alteration, measured by skin hydration, is a key element for evaluation of emollient
treatment efficacy.
The primary objective of this study is to demonstrate the efficacy of the tested product
(V0034CR01B) cream on xerosis in children with atopic dermatitis compared to the excipient
formula during 28 days.
Clinical Details
Official title: Efficacy of the V0034CR01B Emollient on Xerosis in Children With Atopic Dermatitis. Randomised, Vehicle-controlled, Parallel-groups, Double-blind Study With an Open Label Extension.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Xerosis score: mean evolution over the different time-points of double-blind period
Secondary outcome: Hydration Index score : measurement of the skin hydrationXerosis score evolution over the different time-ponts during open label period Xerosis Visual Analogue Scale (evaluation skin dryness) Scoring for Atopic Dermatitis (SCORAD) : measurement of objective symptoms of Atopic Dermatitis. Overall assessment of treatment efficacy by the investigator Overall assessment of treatment efficacy and use by the parent(s)/guardian(s) Assessment of the local tolerability and the systemic safety (reported adverse events) Topical corticosteroid assessment
Eligibility
Minimum age: 2 Years.
Maximum age: 6 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Presenting with atopic dermatitis, dry skin, objective SCORAD < 15,
- With xerosis on the body and a xerosis score > = 2 (SCORAD sub-score) on the
anterior part of lower limbs,
Exclusion Criteria:
- Acute phase of atopic dermatitis
- Severe form of atopic dermatitis
Locations and Contacts
Pierre Fabre Medicament, Email: contact_essais_cliniques@pierre-fabre.com
Estonia, Tallinn, Estonia; Recruiting
Estonia, Tartu, Estonia; Recruiting
France, Bordeaux, France; Recruiting
France, Martigues, France; Recruiting
France, Nantes, France; Recruiting
France, Nice, France; Recruiting
France, Poitiers, France; Recruiting
Lithuania, Vilnius, Lithuania; Not yet recruiting
Poland, Białystok, Poland; Not yet recruiting
Poland, Inowrocław, Poland; Not yet recruiting
Poland, Oleśnica, Poland; Not yet recruiting
Poland, Poznań, Poland; Not yet recruiting
Poland, Płock, Poland; Not yet recruiting
Poland, Strzelce Opolskie, Poland; Not yet recruiting
Poland, Warszawa, Poland; Not yet recruiting
Poland, Łódź, Poland; Not yet recruiting
Poland, Żyrardów, Poland; Not yet recruiting
Romania, Brasov, Romania; Not yet recruiting
Romania, Bucharest, Romania; Not yet recruiting
Romania, Constanta, Romania; Not yet recruiting
Romania, Craiova, Romania; Not yet recruiting
Romania, Iasi, Romania; Not yet recruiting
Romania, Ploiesti, Romania; Not yet recruiting
Romania, Sibiu, Romania; Not yet recruiting
Romania, Targu Mures, Romania; Not yet recruiting
Additional Information
Starting date: November 2011
Last updated: December 6, 2011
|